Trexquant Investment’s Adaptimmune Therapeutics ADAP Stock Holding History

Trexquant Investment’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-23,609	Closed	-$122K	–	1263
2021 Q3	$122K	Buy	+23,609	New	+$106K	0.01%	1033
2021 Q2	–	Sell	-46,742	Closed	-$248K	–	1044
2021 Q1	$248K	Buy	+46,742	New	+$268K	0.02%	854
2018 Q3	–	Sell	-15,021	Closed	-$178K	–	919
2018 Q2	$178K	Buy	+15,021	New	+$187K	0.01%	803
2018 Q1	–	Sell	-27,113	Closed	-$181K	–	1031
2017 Q4	$181K	Buy	+27,113	New	+$209K	0.02%	957

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Trexquant Investment's ADAP Position: Q4 2021 in Review

Trexquant Investment sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 23,609 shares — an estimated $122K sold.

Trexquant Investment first reported a position in ADAP in Q4 2017 and held it in 4 quarters. The position peaked at $248K in Q1 2021. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

Trexquant Investment reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
Trexquant Investment sold 23,609 Adaptimmune Therapeutics shares in Q4 2021, an estimated $122K.
Trexquant Investment first reported a position in Adaptimmune Therapeutics in Q4 2017 and held it in 4 quarters.
Trexquant Investment's Adaptimmune Therapeutics position peaked at $248K in Q1 2021.
85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on Trexquant Investment's 13F filing for Q4 2021, filed 14 Feb 2022.